Autolus

Q3 2026 Financial Results and Business Updates



November 10, 2026

For Investor communication only. Not for use in product promotion. Not for further distribution.

Disclaimer

These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to, statements regarding Autolus’ 2026 AUCATZYL net product revenue and gross margin guidance; anticipated cash runway; commercialization and manufacturing plans for AUCATZYL; expansion into additional markets and indications; and the timing, progress and results of clinical studies of obe-cel and other product candidates. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: Autolus' ability to maintain regulatory approval of AUCATZYL; its ability to execute its commercialization strategy for AUCATZYL; its ability to develop, manufacture and commercialize its other product candidates and the timing or likelihood of expansion of AUCATZYL into additional markets or geographies; Autolus' ability to maintain a commercial infrastructure and to successfully launch, market and sell AUCATZYL; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; the labelling for AUCATZYL/obe-cel in any future indication or patient population, if approved; the potential for payors to delay, limit or deny coverage for AUCATZYL; Autolus' ability to obtain, maintain and enforce intellectual property protection for AUCATZYL or any product candidates it is developing; the results of clinical trials are not always being predictive of future results; the cost, timing and results of clinical trials; that many product candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; and possible safety and efficacy concerns. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus’ actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in Autolus' Annual Report on Form 10-K filed with the Securities and Exchange Commission, or the SEC, on March 27, 2026, as well as discussions of potential risks, uncertainties, and other important factors in Autolus’ subsequent filings with the Securities and Exchange Commission. All information in this presentation is as of the date of the presentation, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing the Company’s views as of any date subsequent to the date of this presentation.

Agenda

- Welcome and Introduction: Amanda Cray, ED, Investor Relations & External Communications
- Operational Highlights: Dr. Christian Itin, CEO
- Financial Results: Rob Dolski, CFO
- Upcoming Milestones and Conclusion: Dr. Christian Itin, CEO
- Q&A: Dr. Christian Itin and Rob Dolski

Strong AUCATZYL® sales growth in 2026

Global Net Product Revenue

Q3 2026: $41.2 million — +95% vs Q3 2025

9M 2026: $113.1 million — +122% vs 9M 2025

Growth Drivers

- Growing demand in existing U.S. treatment centers as physicians gain positive experience with AUCATZYL
- New treatment centers coming online expand access in the U.S.
- Additional ROCCA real-world data expected in December 2026
- UK sales supplement growth in U.S. product demand

90 U.S. Authorized Treatment Centers

Autolus™ Assist



Executing to the commercial plan in 2026

2026 Expectations & Financial Guidance

FY 2026 Net Product Revenue

Expect to be at or exceeding upper end of **$150 million** from prior guidance range

Achieved: Positive Gross Margin in 2026

Q3 gross margin of 57%

YTD gross margin of 44%

Supported by volumes and manufacturing efficiencies

Commercial Expansion

Achieved: Increase commercial footprint in the US to more than **80** treatment centers



Path to profitability in the r/r B-ALL business


Optimizing the operating model and driving cost efficiency

Increasing volumes and operational efficiency initiatives producing gross margin improvements

We are here

- ✓ Launch: Establish consistent and high-quality product supply and service
- Optimization: Improve efficiency and increase volumes to drive margins
- Peak: expect gross profit margin of 65-70%

Gross Margin %*



44%
Year-to-date gross margin

Expect continued improvement with volumes and cost efficiencies

*Gross margin = (net product revenue less cost of sales) / net product revenue.

Pipeline-in-a-product: expanding obe-cel's potential beyond adult B-ALL

FDA granted RMAT designation for obe-cel in SLE and lupus nephritis on September 9, 2026

Timing	Program	Update	Indication	Trial
Nov 10, 2026	Obe-cel	Longer-term follow up from Phase 1	Systemic Lupus (SLE)	CARLYSLE Phase 1
Dec 2026	AUTO8	Initial Phase 1 data	AL Amyloidosis	ALARIC Phase 1
2H 2027	Obe-cel	Phase 1 data	Progressive Multiple Sclerosis	BOBCAT Phase 1
End of 2027	Obe-cel	Phase 2 data	Pediatric r/r B-ALL	CATULUS Phase 1/2
2028	Obe-cel	Phase 2 data	Lupus Nephritis (LN)	LUMINA Phase 2

Oncology Autoimmune / B Cell Mediated Disease

Upcoming data update: BOBCAT Trial in Progressive MS

Q1 2027 Data Plan Update

Data presentation now 2H 2027

- Patient enrollment moving to plan with last patient expected to be enrolled in Q1 2027
- Consistent KOL feedback at ACTRIMS-ECTRIMS Global Meeting, Oct 2026 in Toronto indicated a need for 12-24 months of follow-up to assess clinical data in PMS
- Initial data presentation planned for 2H 2027

2H 2027: ECTRIMS

Initial Phase 1 data update will now include:

- Total of 24 patients, with 12 patients at 12+ months of follow up
  - Clinical response assessment
  - Imaging data
  - Expanded safety, PK/PD & biomarker data
  - Potential path for next development and regulatory activities

Progress across the autoimmune portfolio: CARLYSLE trial in SLE to be reported today at ACR
Longer-term follow up data show obe-cel activity and long-term durability consistent with expected biology, supporting the broader autoimmune scientific rationale.

Financial Results

Financial summary – key metrics*

USD ($' 000)	Q3 2026	Q3 2025	Variance
Product revenue, net	**41,238**	**21,144**	**20,094**
Cost and operating expenses:			
Cost of sales	(17,927)	(28,643)	10,716
Research and development expenses, net	(30,900)	(27,892)	(3,008)
Selling, general and administrative expenses	(35,946)	(36,280)	334
Loss from operations	**(43,535)**	**(71,621)**	**28,086**
Total comprehensive loss	**(54,613)**	**(84,900)**	**30,287**

*Select metrics only; for full financials please refer to the Company's 10-Q filing

Cash, cash equivalents & marketable securities

$248.4M

As of September 30, 2026

Capital base strengthened by the Perceptive credit facility

Autolus expects that its current and projected cash, cash equivalents and marketable securities, including the combined first and second tranches totaling $100M from the credit facility, will be sufficient to **fund the Company's operations into Q2 2028**.

Conclusion

Autolus is positioned for value creation

Obe-cel product franchise supports multiple growth opportunities

Initial Indication: Adult r/r B-ALL

Strong execution and market expansion

AUCATZYL® obecabtagene autoleucel
suspension for IV infusion

9M 2026 Net Product Revenue

$113.1 million

- 2026 net product revenue at or exceeding $150M, top of prior guidance range
- Significant opportunity to grow overall CAR T market in adult r/r B-ALL
- Physician interest to pursue investigator sponsored trials in 1st line ALL

Pipeline expansion opportunities grow future commercial potential in new indications

Product	Indication	Target	Preclinical	Phase 1	Phase 2/Pivotal	Approved
AUCATZYL®	Adult ALL	CD19				
obe-cel	Pediatric ALL	CD19				
obe-cel	Lupus Nephritis	CD19				
obe-cel	Progressive Multiple Sclerosis	CD19				

- Enrollment ongoing in Phase 2 lupus nephritis and pediatric ALL trials and the Phase 1 progressive MS trial
- CARLYSLE at ACR and ALARIC at ASH in 2026, followed by BOBCAT and CATULUS data in 2027

Commercial and pipeline opportunities supported by proven manufacturing and product delivery capabilities and established authorized treatment centers

Autolus

Thank you